EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Optimal duration of levetiracetam prophylaxis following supratentorial tumor resection: a multi-study analysis

Kenan Kıbıcı, Nur Ozturk, Nilay Aksoy

Neurosurgical Review · 06.11.2026 · 49 (1)

DOI: 10.1007/s10143-026-04549-7 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Neurosurgical Review, online erschienen am 06.11.2026. Verfasst von Kenan Kıbıcı und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, School of Medicine Bahcelievler Medical Park Hospital, Altinbas University, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Anticonvulsants, Levetiracetam, Postoperative Complications, Seizures. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the efficacy and safety of short-course (≤ 9 days) versus extended-course levetiracetam (LEV) prophylaxis for preventing seizures in seizure-naïve patients following supratentorial tumor resection. A systematic review and meta-analysis were conducted across PubMed, Google Scholar, and the Cochrane Library. Eight studies encompassing nine distinct clinical cohorts (N = 385) were included. Studies were dichotomized into Short-Term (ST: ≤ 9 days) and Extended-Term (ET: > 9 days) groups. Pooled seizure incidence was analyzed using a random-effects model, and a multivariate meta-regression isolated drivers of seizure risk. A temporal crossover analysis mapped medication attrition against marginal prophylactic benefit. The ST group demonstrated a pooled seizure incidence of 2.4% (95% CI: 1.1%-4.6%), significantly below the 12% historical baseline. Conversely, ET cohorts exhibited higher, volatile rates (up to 34.7%), statistically indistinguishable from untreated late-onset benchmarks (20%). Meta-regression identified only treatment duration and tumor type as significant moderators of outcomes (p < 0.05); age, gender, and LEV dosage (1000-3000 mg) had no impact. Safety analysis revealed a day-14 "clinical pivot": early well-tolerated somatic effects transitioned to severe neuropsychiatric toxicity with extended therapy, driving high attrition rate. ST (≤ 9 days) LEV protocol provides maximal prophylactic efficacy with minimal toxicity. Extending prophylaxis beyond this window offers no incremental protection against late-onset seizures but subjects patients to an intolerable neuropsychiatric burden. While prospective control trials are necessary to establish definitive guidelines, our findings indicate that a short term LEV course may offer a highly favorable risk-benefit profile. Extending prophylaxis beyond this timeframe seems to offer minimal additional benefit while markedly elevating the risk of neu​ropsychiatric toxicity, thereby requiring prudent clinical evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsLevetiracetamPostoperative ComplicationsSeizuresSupratentorial NeoplasmsHumansTreatment Outcome

Stichwörter der Autor:innen

LevetiracetamProphylaxis durationSeizure prophylaxisSupratentorial tumor resection

Substanzen

AnticonvulsantsLevetiracetam

Autor:innen und Institutionen

  • Department of Neurosurgery, School of Medicine Bahcelievler Medical Park Hospital, Altinbas University, Istanbul, Türkiye.
  • Department of Clinical Pharmacy, School of Pharmacy, Altinbas University, Istanbul, Türkiye.
  • Department of Clinical Pharmacy, School of Pharmacy, Altinbas University, Istanbul, Türkiye. Nilay.aksoy@altinbas.edu.tr.

Zitieren

APA

Kıbıcı, K., Ozturk, N., & Aksoy, N. (2026). Optimal duration of levetiracetam prophylaxis following supratentorial tumor resection: a multi-study analysis. Neurosurgical Review, 49(1). https://doi.org/10.1007/s10143-026-04549-7

Vancouver

Kıbıcı K, Ozturk N, Aksoy N. Optimal duration of levetiracetam prophylaxis following supratentorial tumor resection: a multi-study analysis. Neurosurgical Review. 2026;49(1). doi:10.1007/s10143-026-04549-7

BibTeX
@article{Kbc2026,
  author = {Kıbıcı, Kenan and Ozturk, Nur and Aksoy, Nilay},
  title = {Optimal duration of levetiracetam prophylaxis following supratentorial tumor resection: a multi-study analysis},
  journal = {Neurosurgical Review},
  year = {2026},
  volume = {49},
  number = {1},
  doi = {10.1007/s10143-026-04549-7}
}
Kostenlos starten →